MyFinsight
Home
Blog
About
Contact
Download
Download image
Comprehensive loss
-$20,915K
(59.69%↑ Y/Y)
Unrealized gain related to
available for sale...
$106K
(-73.83%↓ Y/Y)
Gene Dx
$415,641K
(37.50%↑ Y/Y)
All Other Segments
$1,027K
Gene Dx
$7,447K
(-97.54%↓ Y/Y)
All Other Segments
$3,424K
Net loss
-$21,021K
(59.80%↑ Y/Y)
Income tax benefit
-$116K
(66.18%↑ Y/Y)
Diagnostic Test
$416,668K
Product And Service
Other
$10,871K
Loss before income
taxes
-$21,137K
(59.84%↑ Y/Y)
Total revenue
$427,539K
(41.50%↑ Y/Y)
Loss from operations
-$13,077K
(43.67%↑ Y/Y)
Total non-operating
(expense) income, net
-$8,060K
(72.60%↑ Y/Y)
Gross profit
$298,173K
(53.38%↑ Y/Y)
Cost of services
$129,366K
(16.49%↑ Y/Y)
General and
administrative
$150,819K
(49.16%↑ Y/Y)
Other (expense)
income, net
-$4,317K
(66.83%↑ Y/Y)
Interest (expense)
income, net
-$2,539K
(16.26%↑ Y/Y)
Change in fair value of
financial liabilities
-$1,204K
Selling and marketing
$88,405K
(31.22%↑ Y/Y)
Research and development
$72,026K
(57.53%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
GeneDx Holdings Corp. (WGS)
GeneDx Holdings Corp. (WGS)